United States pharmaceutical preparations industry landscape illustrating listed-company operations, infrastructure and market activity

Prism Finance USA · comparison snapshot

Pharmaceutical Preparations Stocks in USA: Prism Readiness Cohort 32

Name: Pharmaceutical Preparations Stocks in USA: Prism Readiness Cohort 32 comparison snapshot
Creator: Fliar BI Prism

A five-company pharmaceutical preparations cohort selected by Prism readiness, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 01 September 2026Not investment adviceRanked by Prism readiness

Readiness leaderAnaptysBio · 31

Strongest available pathAnaptysBio · +205.8%

Widest latest marginAnaptysBio · -5.6%

Companies compared5 · U.S.-listed

01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1ANAB · Nasdaq

AnaptysBio

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2005San Diego, California$1.64B market cap

View full Companies Radar profile

31Cautious

Snapshot price$55.28as of page date

Monthly-close return+205.8%five-year window

FY2025 revenue$0.23BANAPTYSBIO, INC

Net margin-5.6%FY2025

P/E snapshot12.7xone ratio, not a verdict

Prism attention21.1%share across these five

Filing track recordRevenue, USD billions

+271.4%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 38.8%

52-week position72% through range

$11.40$72.36

News mentions1.0K

Community mentions11partial coverage

U.S.-scope patents326

Prism InsightsWhat sits behind the readiness signal
Observed risk 7/100higher means more observed risk

Earnings signal34/100
Management stability90/100
Market position0/100
Capital-event signal39/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 2 lawsuit, 0 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2ERNA · Nasdaq

Brooklyn ImmunoTherapeutics

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2018New York City$5.1M market cap

View full Companies Radar profile

31Cautious

Snapshot price$4.35as of page date

Monthly-close return-100.0%five-year window

FY2025 revenue$0.00BErnexa Therapeutics Inc.

Net margin-2419.9%FY2025

Prism attention2.5%share across these five

Filing track recordRevenue, USD billions

-97.1%

FY2019–FY2025 · 5 filing periods · TOTAL REVENUE · Revenue derived as cost of revenue plus gross profit for FY2023, FY2024, FY2025 · CAGR -58.6%

52-week position2% through range

$3.18$71.50

News mentions121

Community mentions0partial coverage

U.S.-scope patents11

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal26/100
Management stability90/100
Market position11/100
Capital-event signal25/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 8 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3CVSI · OTC

CV Sciences

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2010Las Vegas, Nevada$4.5M market cap

View full Companies Radar profile

31Cautious

Snapshot price$0.02as of page date

Monthly-close return-91.7%five-year window

FY2025 revenue$0.01BCV Sciences, Inc.

Net margin-6.9%FY2025

Prism attention16.1%share across these five

Filing track recordRevenue, USD billions

-31.2%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -8.9%

52-week position11% through range

$0.01$0.10

News mentions766

Community mentions0partial coverage

U.S.-scope patents21

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal34/100
Management stability90/100
Market position26/100
Capital-event signal0/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 2 M&A involvements, 0 asset-acquisition events and 2 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4TRDA · Nasdaq

Entrada Therapeutics

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2016Boston, Massachusetts$275.3M market cap

View full Companies Radar profile

30Cautious

Snapshot price$7.07as of page date

Monthly-close return-70.5%five-year window

FY2025 revenue$0.03BEntrada Therapeutics, Inc.

Net margin-565.5%FY2025

P/E snapshot-2.3xone ratio, not a verdict

Prism attention9.9%share across these five

Filing track recordRevenue, USD billions

-80.3%

FY2023–FY2025 · 3 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -55.6%

52-week position18% through range

$5.02$16.45

News mentions469

Community mentions1partial coverage

U.S.-scope patents128

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal32/100
Management stability90/100
Market position0/100
Capital-event signal15/100
Innovation pulse5/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5RARE · Nasdaq

Ultragenyx

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2010Novato, California$2.54B market cap

View full Companies Radar profile

29Avoid

Snapshot price$25.81as of page date

Monthly-close return-71.4%five-year window

FY2025 revenue$0.67BUltragenyx Pharmaceutical Inc.

Net margin-85.4%FY2025

P/E snapshot38.8xone ratio, not a verdict

Prism attention50.4%share across these five

Filing track recordRevenue, USD billions

+91.5%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 17.6%

52-week position35% through range

$18.29$39.89

News mentions2.4K

Community mentions26partial coverage

U.S.-scope patents479

Prism InsightsWhat sits behind the readiness signal
Observed risk 19/100higher means more observed risk

Earnings signal38/100
Management stability90/100
Market position9/100
Capital-event signal34/100
Innovation pulse5/100

Management signal

No leadership-churn flag in the model; 2 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 5 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 1 lawsuit, 2 regulatory and 1 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

AnaptysBio

+205.8%

Entrada Therapeutics

-70.5%

Ultragenyx

-71.4%

CV Sciences

-91.7%

Brooklyn ImmunoTherapeutics

-100.0%

Latest revenue

USD billions, official filing scope shown on each company card.

Ultragenyx

$0.67B

AnaptysBio

$0.23B

Entrada Therapeutics

$0.03B

CV Sciences

$0.01B

Brooklyn ImmunoTherapeutics

$0.00B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

AnaptysBio

-5.6%

CV Sciences

-6.9%

Ultragenyx

-85.4%

Entrada Therapeutics

-565.5%

Brooklyn ImmunoTherapeutics

-2419.9%

Prism news attention

Normalized share across these five names; attention is not quality.

Ultragenyx

50.4%

AnaptysBio

21.1%

CV Sciences

16.1%

Entrada Therapeutics

9.9%

Brooklyn ImmunoTherapeutics

2.5%

03 · Prism readout

What the signals say—and what they do not

The headline share is normalized pharmaceutical preparations news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Ultragenyx leads the conversation

It holds 50.4% of measured pharmaceutical preparations news attention and also carries the basket's largest revenue base at $0.67B.

Price path

AnaptysBio leads the available price paths

Its monthly-close return is +205.8% for the five-year window. At the other end, Brooklyn ImmunoTherapeutics is -100.0% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

AnaptysBio has the widest latest margin

Its FY2025 net margin is -5.6%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Entrada Therapeutics shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -2.3x while its five-year window price return is -70.5%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · ANAB

AnaptysBio

1,001available Prism news records

Prism top themes

Price action & investor response

103

Legal, arbitration & regulatory

Leadership & governance

Earnings & financial performance

Capital allocation & transactions

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+7.2%239 latest 12m vs 223 prior 12m

Machine-classified coverage tone

84.5% positive-2.6 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock performance 32stock price 24share price 19adc therapeutics 10phase ii trial 9startup valuation 8phase iii trial 8immunotherapy 7

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-11–2026-06-02 · trend and themes shown through 2026-06

Areas of research · RARE

Ultragenyx

2,397available Prism news records

Prism top themes

Price action & investor response

Legal, arbitration & regulatory

Capital allocation & transactions

Earnings & financial performance

Leadership & governance

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+34.7%501 latest 12m vs 372 prior 12m

Machine-classified coverage tone

77.8% positive-11.8 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

gene therapy rare diseases 202rare disease clinical trials 135rare disease treatment 130ultra-rare diseases 90orphan drug incentives 65orphan drug pricing 62rare disease registries 23orphan drug exclusivity 22

Keyword tag occurrences in available Prism news records.

Coverage: 2010-05-03–2026-06-18 · trend and themes shown through 2026-06

05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

RARE

Ultragenyx

26 mentions

Stock and valuation

Products, pricing and logistics

Workplace and hiring

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 26 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

ANAB

AnaptysBio

through 2026-04-27

Earnings releases 9Listing / IPO 3Lawsuits 2Business contracts 1Company announcements 1

2026-04-27
Lawsuits
TESARO, a subsidiary of GSK plc (LSE/NYSE: GSK), has announced an update regarding its ongoing legal dispute with AnaptysBio, Inc. The Delaware Chancery Court granted AnaptysBio’s motion to dismiss TESARO’s claim for anticipatory breach.
2025-08-07
Earnings releases
Net loss was $38.6 million and $78.0 million for the three and six months ended June 30, 2025, or a net loss per share of $1.34 and $2.62.
2025-06-03
Company announcements
On June 3, 2025, AnaptysBio announced positive results from its Phase 2b RENOIR clinical trial for rosnilimab, a treatment targeting PD-1+ T cells in patients with moderate-to-severe rheumatoid arthritis.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

ERNA

Brooklyn ImmunoTherapeutics

through 2026-09-01

Leadership changes 8M&A 8Earnings releases 3Company announcements 2Funding Rounds 1

2026-09-01
Leadership changes
Prism's available event log records 8 leadership changes for Brooklyn ImmunoTherapeutics.
2026-09-01
M&A
Prism's available event log records 8 m&a for Brooklyn ImmunoTherapeutics.
2026-09-01
Earnings releases
Prism's available event log records 3 earnings releases for Brooklyn ImmunoTherapeutics.

Cached Prism company-event evidence fallback; totals describe available coverage and the displayed highlights prefer filing-backed earnings rows.

CVSI

CV Sciences

through 2026-03-28

Earnings releases 21Business contracts 2M&A 2

2026-03-28
Earnings releases
In the fourth quarter, revenue was $3.3 million versus $3.9 million in the year-ago quarter and was consistent with the third quarter of 2025.
2025-07-28
Business contracts
Las Vegas-based CV Sciences (CVSI) announced Wednesday that its CBD oil will be sold in 945 Kroger-owned stores spanning 17 U.S. states.
2024-05-14
M&A
CV Sciences, Inc. (OTCQB:CVSI), a prominent consumer wellness company focusing on hemp extracts and other science-backed natural ingredients, has completed the acquisition of Elevated Softgels, LLC.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

TRDA

Entrada Therapeutics

through 2024-03-13

Earnings releases 4Lawsuits 1Leadership changes 1

2024-03-13
Earnings releases
Entrada Therapeutics missed estimated earnings by -71.0%, reporting an EPS of $-0.29 versus an estimate of $-0.17.
2024-01-03
Leadership changes
Entrada Therapeutics announced that Nathan Dowden, current Chief Operating Officer of Entrada Therapeutics, has been promoted to President and Chief Operating Officer, effective as of January 1, 2024.
2023-02-06
Lawsuits
Pomerantz LLP is investigating claims on behalf of investors of Entrada Therapeutics, Inc. ("Entrada" or the "Company") (NASDAQ: TRDA).

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

RARE

Ultragenyx

through 2026-03-24

Earnings releases 33Company announcements 4Regulatory 2Lawsuits 1Leadership changes 1

2026-03-24
Lawsuits
A deadline is coming up on April 6, 2026 in the lawsuit filed for certain investors of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) over alleged securities laws violations by Ultragenyx Pharmaceutical Inc.
2026-02-12
Earnings releases
Total revenue for the year ended December 31, 2025 was $673 million, which represents 20% growth compared to the prior year, and a net loss of $575 million.
2025-10-02
Regulatory
While reporting Breakthrough Therapy designation for GTX-102 in Angelman syndrome, Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) appears to be in a good position to advance UX143, which will be a transformational treatment for pediatric and adult patients with osteogenesis imperfecta.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Pharmaceutical Preparations Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary pharmaceutical preparations news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

pharmaceutical industry

36 sources100.0% extraction confidence

2011 extracted base$66.70B

2016 extracted forecast$42.00B–$70.00B

Implied source CAGR9.5%

Macro and micro trends driving the industry's futureR&D expenditure and leading therapeutic areasGrowth opportunities

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, India, China, U.S.. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Pharmaceutical Preparations news pulse

55,282available Prism news records

Latest 12m volume+3.4%24052 vs 23272 records

Positive classified tone65.3%+6.0 pp vs prior four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Available U.S.-primary Prism records matching pharmaceutical, preparation. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

drug pricing and reimbursement strategies

6,223

snowstorm and blizzard alerts

6,121

pharmaceutical marketing and sales strategies

6,014

winter weather preparedness

5,925

generic drug development and market trends

3,700

healthcare economics and market access

3,498

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

ice storm preparation 6,522snowstorm advisory 5,649cold weather readiness 5,010heavy snow warning 4,972winter storm alert 4,355snow accumulation alert 4,114life-threatening weather 2,915severe weather warning 2,905

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

Macro and micro trends driving the industry's future

36 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card

Opportunity · demand

drug pricing and reimbursement strategies

6,223 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata

Opportunity · innovation

Innovation and product activity

5,689 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule

Caution · market restraint

regulatory changes

5,709 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata

Caution · news pulse

Coverage growth can reverse

+3.4% news volume

The latest 12 months contain 24,052 matched records versus 23,272 in the previous window.

Available Prism coverage through 2026-05-05

Caution · sentiment

Classified tone is not demand

65.3% positive · +6.0pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →

08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 2834 (Pharmaceutical Preparations), selected as the first five names that pass all live publication gates from the Prism readiness candidate pool ranked 156–163. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

Official annual filingsFY revenue history and latest profitability
U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
Prism market-growth extractionDated third-party Pharmaceutical Preparations Industry in USA market benchmark with source-count, geography and confidence context

Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 01 September 2026.

09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions

AnaptysBio leads the readiness ranking

Its Prism readiness score is 31/100, the highest in this five-company comparison.

Open AnaptysBio in Companies Radar

Scale and margin leadership sit with Ultragenyx and AnaptysBio

Ultragenyx has the largest displayed latest revenue at $0.67B; AnaptysBio has the widest displayed latest margin at -5.6%.

Open Ultragenyx in Companies Radar Open AnaptysBio in Companies Radar

Comparisons

Strongest versus weakest available price path

AnaptysBio is +205.8% for its five-year window; Brooklyn ImmunoTherapeutics is -100.0% for its five-year window.

Open AnaptysBio in Companies Radar Open Brooklyn ImmunoTherapeutics in Companies Radar

Largest versus smallest displayed revenue base

The latest displayed revenue ranges from $0.67B for Ultragenyx to $0.00B for Brooklyn ImmunoTherapeutics. Entity and filing-period labels remain visible on the company cards.

Open Ultragenyx in Companies Radar Open Brooklyn ImmunoTherapeutics in Companies Radar

Anomalies

Ultragenyx has the widest attention-readiness rank gap

It ranks #1 by measured news attention (50.4%) and #5 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open Ultragenyx in Companies Radar

Ultragenyx shows a price-operating divergence to inspect

Its displayed filing-revenue change is +91.5% while its available monthly-close return is -71.4%. The signs differ, but the two measures cover different windows and do not establish causality.

Open Ultragenyx in Companies Radar

Explanations

Attention measures coverage volume, not quality

Ultragenyx's 50.4% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Ultragenyx in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open AnaptysBio's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 31/100 score.

Open AnaptysBio in Companies Radar

Stress-test the largest divergence before forming a view

Compare Ultragenyx's profile with AnaptysBio's profile, then reconcile the displayed filing and price windows. This is a next-research action, not a buy or sell decision.

Open Ultragenyx in Companies Radar Open AnaptysBio in Companies Radar

Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.